Maria O'Donovan

Appearances

MODELLING FROM A MULTICENTRE, PRAGMATIC, RANDOMISED CONTROLLED TRIAL IDENTIFIES THE TARGET SCREENING POPULATION AND EXPECTED YIELD FOR BARRETT’S ESOPHAGUS AND ESOPHAGEAL CANCER DIAGNOSES
Date
May 20, 2024
Screening for Barrett’s esophagus (BE) could lead to earlier detection and improved survival of esophageal adenocarcinoma (EAC)…
Presenter
W. Keith Tan
Speakers
Roberta Maroni
Judith Offman
Shahriar Zamani
Massimiliano Di Pietro
Maria O'Donovan
Peter Sasieni
Rebecca Fitzgerald
UTILITY OF A MULTI-GENE METHYLATION PANEL TO RISK-STRATIFY PATIENTS WITH BARRETT’S ESOPHAGUS AFTER RADIOFREQUENCY ABLATION
Date
May 18, 2024
Radiofrequency ablation (RFA) is effective to eradicate dysplastic Barrett’s esophagus (BE), however recurrence occurs in up to 25% of cases, typically at the gastro-esophageal junction (GEJ)…
Presenter
W. Keith Tan
Speakers
Spyridoula Massia
Daniel Hayward
Guiomar Moral Villarejo
Samantha Warburton
Ines Modolell
Vianca Shah
Hannah Coles
Shahriar Zamani
Michele Bianchi
Maria O'Donovan
Jacobo Ortiz Fernández-Sordo
Massimiliano Di Pietro
BIOMARKER RISK STRATIFICATION USING THE CAPSULE SPONGE FOR THE SURVEILLANCE OF BARRETT'S ESOPHAGUS: INTERIM RESULTS FROM THE UK REAL-WORLD IMPLEMENTATION PILOTS.
Date
May 19, 2024
Endoscopic surveillance is recommended for Barrett’s esophagus (BE), but the effectiveness is questionable and varies according to expertise. Pan-oesophageal cell collection devices with biomarkers offer a less operator dependent alternative…
Presenter
W. Keith Tan
Speakers
Massimiliano Di Pietro
Maria O'Donovan
Craig Vickery
Nicola Gogin
Ita Boyle
Evelyn Caspillo
Jacquelyn Harvey
Kim Shaw
Danielle Morris
Rebecca Fitzgerald